College Call Girls Pune Mira 9907093804 Short 1500 Night 6000 Best call girls...
GINA 2019 presentation
1. Global Strategy for Asthma
Management and Prevention
(2019 update)
Dr. Md. Shafiqul Islam Dewan
Phase-A Resident (Pulmonology)
Medicine Unit - VIII
Dhaka Medical College Hospital
2. About GINA
GINA stands for Global Initiative for Asthma.
Established in 1993.
Work with health care professionals and public
health officials around the world.
To reduce asthma prevalence, morbidity, and
mortality.
3. Asthma
Asthma is a heterogeneous disease.
Characterized by chronic airway inflammation.
Causing symptoms such as wheezing, shortness of
breath, chest tightness and cough.
That varies in frequency and intensity together
with variable expiratory airflow limitation.
4. Phenotypes of Asthma
Many phenotypes have been identified. Most
common phenotypes are:
Allergic asthma
Non-allergic asthma
Adult-onset (Late onset) asthma
Asthma with fixed airway limitation
Asthma with obesity
5. Diagnosis of Asthma
Diagnosis of asthma depends on two
defining features:
History of respiratory symptoms such as
wheeze, shortness of breath, chest tightness
and cough that vary over time and in intensity.
Variable expiratory airflow limitation.
6.
7. Patient with respiratory symptoms
Are the symptoms typical of
Asthma?
Details History and Examination
History and Examination Supports
Asthma Diagnosis?
Perform Spirometry / PEF with
Reversibility test
Result Support Asthma Diagnosis?
Treat for Asthma
Yes
Yes
Yes
Empiric treatment
with ICS and prn SABA
Review response
Diagnostic testing
within 1-3 months Treat for Alternative
Diagnosis
Further History &
Test for Alternative
Diagnosis
Clinical urgency
Other diagnosis
unlikely
No
Y
e
s
Diagnostic flow-chart for Asthma in clinical practice
8. Assessing a patient with Asthma
Assess asthma control
Assess risk factor
Assess for comorbidities
Assess treatment issue
9. Assess asthma control
Level of asthma symptom control.
In the past 4 weeks,
has the patient had
Well
controlled
Partly
controlled
Uncontrolled
Daytime symptoms more
than twice/week?
Yes/No
None of
these
1 - 2
of these
3 - 4
of these
Reliever needed more
than twice/week?
Yes/No
Any night waking due to
asthma?
Yes/No
Any activity limitation
due to asthma?
Yes/No
10. Assess risk factor
Risk factor for exacerbations
Risk factors for developing fixed airflow
limitation
Risk factors for medication side-effects
11. Risk factor for exacerbations
Uncontrolled asthma symptoms
Comorbidities
Exposures to smoking, allergen and air pollution
Major socioeconomic problems
Medication: Inhaled corticosteroid (ICS) not
prescribed, Poor adherence, Incorrect inhaler
technique, High (SABA) use.
12. Risk factors for developing fixed airflow limitation
Preterm birth, LBW and greater infant weight gain.
Lack of ICS treatment
Exposure to tobacco smoke and noxious chemicals
Low FEV1
Chronic mucus hyper-secretion
Sputum or blood eosinophilia
13. Risk factors for medication side-effects
Frequent oral corticosteroid use.
Long term high-dose or potent ICS use.
Poor inhaler technique.
15. Assess treatment issue
Record the patient’s treatment and ask about side
effects.
Check that the patient has a written asthma
action plan.
Ask the patient about their attitudes and goals for
their asthma.
16. Written asthma action plan
The written asthma action plan should
include:
The patient’s usual asthma medications
When and how to increase medications and
start oral corticosteroid(OCS)
How to access medical care if symptoms fail to
respond
17. Management of Asthma
Few asthma symptoms
No sleep disturbance
No exercise limitation
Maintain normal lung function
Prevent flare-ups (exacerbations)
Prevent asthma deaths
Avoid medication side-effects
Symptom control
Risk reduction
18. Management of Asthma
General management
Asthma medication
Treatment of modifiable risk factor
Treatment of comorbidity
Non pharmacological therapies and strategies
Follow up
19. General management
Patient education regarding Asthma
Inhaler skills
Adherence
Written asthma action plan
Self-monitoring of symptoms and/or peak flow
Regular medical review
27. Add-on Controller Medication
Long-acting anticholinergic (At Step 4 or 5 with a
history of exacerbations despite ICS ± LABA)
Tiotropium
Anti-IgE (with severe allergic asthma uncontrolled
on high dose ICS-LABA)
Omalizumab
28. Add-on Controller Medication
Anti-IL5 & Anti-IL5R (Severe eosinophilic asthma
uncontrolled on high dose ICS-LABA)
Mepolizumab & Reslizumab
Benralizumab
Anti-IL4R (Severe eosinophilic asthma uncontrolled on
high dose ICS-LABA, or requiring maintenance OCS)
Dupilumab
34. Non pharmacological therapies and strategies
Cessation of smoking
Physical activity
Healthy diet
Weight reduction
Breathing exercises
Avoidance of occupational exposures
35. Non pharmacological therapies and strategies
Avoidance of indoor allergens and air pollution
Avoidance of outdoor air pollutants / weather
conditions
Avoidance of medications that may make asthma
worse
37. Starting asthma treatment
ICS-containing treatment should be initiated as soon
as possible after the diagnosis of asthma is made.
Consider starting at a higher step (e.g. medium/high
dose ICS, or low-dose ICS-LABA) if on most days the
patient has troublesome asthma symptoms; or is
waking from asthma once or more a week.
38. Starting asthma treatment
If the initial asthma presentation is with severely
uncontrolled asthma, or with an acute exacerbation,
give a short course of OCS and start regular controller
treatment (e.g. medium dose ICS-LABA).
Consider stepping down after asthma has been well-
controlled for 3 months. However, in adults and
adolescents, ICS should not be completely stopped.
39. Before starting initial controller treatment
Record evidence for the diagnosis of asthma, if
possible.
Document symptom control and risk factors.
Assess lung function, when possible.
Train the patient to use the inhaler correctly and
check their technique.
Schedule a follow-up visit.
40. After starting initial controller treatment
Review response after 2–3 months, or according
to clinical urgency.
Review for ongoing treatment and other key
management issues.
Consider step down when asthma has been well-
controlled for 3 months
41. Reviewing response and adjusting treatment
Patients should preferably be seen 1–3 months
after starting treatment
Every 3–12 months after that, but in pregnancy,
asthma should be reviewed every 4–6 weeks.
After an exacerbation, a review visit within 1
week should be scheduled
42. Stepping up asthma treatment
• Sustained step-up (for at least 2–3 months): if symptoms
and/or exacerbations persist despite 2–3 months of
controller treatment, assess the following common
issues before considering a step-up
• Incorrect inhaler technique
• Poor adherence
• Modifiable risk factors
• Comorbid conditions
43. Stepping up asthma treatment
Short-term step-up (for 1–2 weeks) by
clinician or by patient with written asthma
action plan, e.g. during viral infection or
allergen exposure.
44. Stepping up asthma treatment
• Day-to-day adjustment by patient for those
who prescribed as-needed low dose ICS-
formoterol for mild asthma, or low dose
ICS-formoterol as maintenance and reliever
therapy.
45. Stepping down asthma treatment
Consider stepping down treatment once
good asthma control has been achieved and
maintained for 3 months, to find the lowest
treatment that controls both symptoms and
exacerbations, and minimizes side-effects.
46. Stepping down asthma treatment
Choose an appropriate time for step-down (no
respiratory infection, patient not travelling, not
pregnant).
Document baseline status (symptom control and
lung function), provide a written asthma action
plan, monitor closely and book a follow-up visit.
49. GINA 2019 – Changes in asthma management
For safety, GINA no longer recommends SABA-
only treatment for Step 1
This decision was based on evidence that SABA-only
treatment increases the risk of severe exacerbations,
and that adding any ICS significantly reduces the risk
GINA now recommends that all adults and
adolescents with asthma should receive symptom-
driven or regular low dose ICS-containing
controller treatment, to reduce the risk of serious
exacerbations
This is a population-level risk reduction strategy, e.g.
statins, anti-hypertensives.
50. Background to changes in 2019
Risks of mild asthma
Patients with apparently mild asthma are at risk
of serious adverse events
30–37% of adults with acute asthma
16% of patients with near-fatal asthma
15–20% of adults dying of asthma
Exacerbation triggers are variable (viruses,
pollens, pollution, poor adherence)
had symptoms less
than weekly in previous
3 months (Dusser,
Allergy 2007)
51. Background to changes in 2019
risks of SABA-only treatment
Inhaled SABA has been first-line treatment for
asthma for 50 years
Patient satisfaction with, and reliance on, SABA
treatment is reinforced by its rapid relief of symptoms,
its prominence in emergency department and hospital
management of exacerbations, and low cost
Patients commonly believe that “My reliever gives me
control over my asthma”, so they often don’t see the
need for additional treatment
52. Background to changes in 2019
risks of SABA-only treatment
Regular or frequent use of SABA is associated
with adverse effects
β-receptor downregulation, decreased
bronchoprotection, rebound hyperresponsiveness,
decreased bronchodilator response (Hancox, Respir Med 2000)
Increased allergic response, and increased eosinophilic
airway inflammation (Aldridge, AJRCCM 2000)
53. Background to changes in 2019
risks of SABA-only treatment
Higher use of SABA is associated with adverse
clinical outcomes
Dispensing of ≥3 canisters per year (average 1.7
puffs/day) is associated with higher risk of emergency
department presentations (Stanford, AAAI 2012)
Dispensing of ≥12 canisters per year is associated with
higher risk of death (Suissa, AJRCCM 1994)
54. GINA 2019 - Stepwise treatment
PREFERRED
CONTROLLER
to prevent exacerbations
and control symptoms
PREFERRED
RELIEVER
Other
reliever option
STEP 1
As-needed
low dose
ICS-formoterol *
Low dose ICS
taken whenever
SABA is taken†
STEP 2
Daily low dose inhaled corticosteroid (ICS), or as-
needed low dose ICS-formoterol *
Leukotriene receptor antagonist (LTRA), or
low dose ICS taken whenever SABA taken †
STEP 3
Low dose
ICS-LABA
Medium dose
ICS, or
low dose
ICS+LTRA #
STEP 4
Medium dose
ICS-LABA
High dose
ICS, add-on
tiotropium,
or add-on
LTRA #
STEP 5
High dose
ICS-LABA
Refer for
phenotypic
assessment
± add-on
therapy,
e.g.tiotropium,
anti-IgE,
anti-IL5/5R,
anti-IL4R
Add low dose
OCS, but
consider
side-effects
As-needed low dose ICS-formoterol * As-needed low dose ICS-formoterol ‡
As-needed short-acting β2 -agonist (SABA)
* Off-label; data only with budesonide-formoterol (bud-form)
† Off-label; separate or combination ICS and SABA inhalers
‡ Low-dose ICS-form is the reliever for patients prescribed bud-
form or BDP-form maintenance and reliever therapy
# Consider adding HDM SLIT for sensitized patients with allergic
rhinitis and FEV >70%predicted
Asthma medication options:
Adjust treatment up and down for
individual patient needs
Other
Controller option
56. GINA 2019 – Step 1 Changes
PREFERRED
CONTROLLER
to prevent exacerbations
and control symptoms
PREFERRED
RELIEVER
Other
reliever option
STEP 1
As-needed
low dose
ICS-formoterol *
Low dose ICS
taken whenever
SABA is taken†
STEP 2
Daily low dose inhaled corticosteroid (ICS), or as-
needed low dose ICS-formoterol *
Leukotriene receptor antagonist (LTRA), or
low dose ICS taken whenever SABA taken †
STEP 3
Low dose
ICS-LABA
Medium dose
ICS, or
low dose
ICS+LTRA #
STEP 4
Medium dose
ICS-LABA
High dose
ICS, add-on
tiotropium,
or add-on
LTRA #
STEP 5
High dose
ICS-LABA
Refer for
phenotypic
assessment
± add-on
therapy,
e.g.tiotropium,
anti-IgE,
anti-IL5/5R,
anti-IL4R
Add low dose
OCS, but
consider
side-effects
As-needed low dose ICS-formoterol * As-needed low dose ICS-formoterol ‡
As-needed short-acting β2 -agonist (SABA)
* Off-label; data only with budesonide-formoterol (bud-form)
† Off-label; separate or combination ICS and SABA inhalers
‡ Low-dose ICS-form is the reliever for patients prescribed bud-
form or BDP-form maintenance and reliever therapy
# Consider adding HDM SLIT for sensitized patients with allergic
rhinitis and FEV >70%predicted
Asthma medication options:
Adjust treatment up and down for
individual patient needs
Other
Controller option
Previously, no controller was
recommended for
Step 1, i.e. SABA-only
treatment was preferred.
57. Step 1 - ‘preferred’ controller option
Step 1 is for patients with symptoms less than twice a
month, and with no exacerbation risk factors
As-needed low dose ICS-formoterol (off-label)
• Evidence
• Indirect evidence from SYGMA 1 of large reduction in severe
exacerbations vs SABA-only treatment in patients eligible for Step 2
therapy (O’Byrne, NEJMed 2018)
• Values and preferences
• High importance given to reducing exacerbations
• High importance given to avoiding conflicting messages about goals
of asthma treatment between Step 1 and Step 2
• High importance given to poor adherence with regular ICS in
patients with infrequent symptoms, which would expose them to
risks of SABA-only treatment
58. Step 1 - other controller option
Low dose ICS taken whenever SABA is taken (off-label)
Evidence
Indirect evidence from studies in patients eligible for Step 2
treatment (BEST, TREXA, BASALT)
Values and preferences
High importance given to preventing severe exacerbations
Lower importance given to small differences in symptom control
and the inconvenience of needing to carry two inhalers
Combination ICS-SABA inhalers are available in some countries, but
approved only for maintenance use
Daily ICS is no longer listed as a Step 1 option
This was included in GINA 2014-18, but with high probability of
poor adherence
Now replaced by more feasible as-needed controller options for
Step 1
60. GINA 2019 - Step 2 changes
PREFERRED
CONTROLLER
to prevent exacerbations
and control symptoms
PREFERRED
RELIEVER
Other
reliever option
STEP 1
As-needed
low dose
ICS-formoterol *
Low dose ICS
taken whenever
SABA is taken†
STEP 2
Daily low dose inhaled corticosteroid (ICS), or as-
needed low dose ICS-formoterol *
Leukotriene receptor antagonist (LTRA), or
low dose ICS taken whenever SABA taken †
STEP 3
Low dose
ICS-LABA
Medium dose
ICS, or
low dose
ICS+LTRA #
STEP 4
Medium dose
ICS-LABA
High dose
ICS, add-on
tiotropium,
or add-on
LTRA #
STEP 5
High dose
ICS-LABA
Refer for
phenotypic
assessment
± add-on
therapy,
e.g.tiotropium,
anti-IgE,
anti-IL5/5R,
anti-IL4R
Add low dose
OCS, but
consider
side-effects
As-needed low dose ICS-formoterol * As-needed low dose ICS-formoterol ‡
As-needed short-acting β2 -agonist (SABA)
* Off-label; data only with budesonide-formoterol (bud-form)
† Off-label; separate or combination ICS and SABA inhalers
‡ Low-dose ICS-form is the reliever for patients prescribed bud-
form or BDP-form maintenance and reliever therapy
# Consider adding HDM SLIT for sensitized patients with allergic
rhinitis and FEV >70%predicted
Asthma medication options:
Adjust treatment up and down for
individual patient needs
Other
Controller option
61. Step 2 - there are two ‘preferred’ controller options
(1) Regular low dose ICS with as-needed SABA
• Evidence
A large body of evidence from RCTs and observational
studies that low dose ICS substantially reduces risks of
severe exacerbations, hospitalizations and death
e.g. Suissa, NEJMed 2000; Suissa, Thorax 2002; Pauwels, Lancet 2003; O’Byrne,
AJRCCM 2001
Serious exacerbations halved even in patients with
symptoms 0-1 days per week (Reddel, Lancet 2017)
Improved symptom control and reduced exercise-
induced bronchoconstriction
62. Step 2 - there are two ‘preferred’ controller options
(1) Regular low dose ICS with as-needed SABA
Values and preferences
High importance was given to preventing asthma
deaths and severe exacerbations.
However, we were aware that poor adherence is
common in mild asthma in the community, and that
this would expose patients to the risks of SABA-only
treatment.
63. Step 2 - two ‘preferred’ controller options
(2) As-needed low dose ICS-formoterol
(off-label; all evidence with budesonide-formoterol)
Evidence
Direct evidence from two large studies of non-
inferiority for severe exacerbations vs daily low dose
ICS + as-needed SABA (O’Byrne, NEJMed 2018, Bateman, NEJMed 2018)
Direct evidence from one large study of 64% reduction
in severe exacerbations vs SABA-only treatment (O’Byrne,
NEJMed 2018)
Symptoms reduced; one study showed reduced
exercise-induced bronchoconstriction.
64. Step 2 - two ‘preferred’ controller options
(2) As-needed low dose ICS-formoterol
Values and preferences
High importance was given to preventing severe
exacerbations, avoiding need for daily ICS in patients with
mild or infrequent symptoms, and safety of as-needed ICS-
formoterol in maintenance and reliever therapy, with no
new safety signals
Lower importance given to small non-cumulative differences
in symptom control (ACQ-5 difference 0.15 vs MCID 0.5) and
lung function compared with daily ICS
Makes use of normal patient behavior (seeking symptom
relief) to deliver controller
65. Step 2 - other controller options
Low dose ICS taken whenever SABA taken
(off-label, separate or combination inhalers)
Evidence
Two RCTs showed reduced exacerbations compared
with SABA-only treatment
BEST, in adults, with combination ICS-SABA (Papi, NEJMed 2007)
TREXA, in children/adolescents, with separate inhalers (Martinez,
Lancet 2011)
Three RCTs showed similar or fewer exacerbations
compared with maintenance ICS
TREXA, BEST
BASALT in adults, separate inhalers, vs physician-adjusted
treatment (Calhoun, JAMA 2012)
66. Step 2 - other controller options
Low dose ICS taken whenever SABA taken
(off-label, separate or combination inhalers)
Values and preferences
High importance given to preventing severe exacerbations
Lower importance given to small differences in symptom
control and the inconvenience of needing to carry two
inhalers
Combination ICS-SABA inhalers are available in some
countries, but approved only for maintenance use
Another option: Leukotriene receptor antagonist
(less effective for exacerbations)
68. GINA 2019 - Step 3 changes
PREFERRED
CONTROLLER
to prevent exacerbations
and control symptoms
PREFERRED
RELIEVER
Other
reliever option
STEP 1
As-needed
low dose
ICS-formoterol *
Low dose ICS
taken whenever
SABA is taken†
STEP 2
Daily low dose inhaled corticosteroid (ICS), or as-
needed low dose ICS-formoterol *
Leukotriene receptor antagonist (LTRA), or
low dose ICS taken whenever SABA taken †
STEP 3
Low dose
ICS-LABA
Medium dose
ICS, or
low dose
ICS+LTRA #
STEP 4
Medium dose
ICS-LABA
High dose
ICS, add-on
tiotropium,
or add-on
LTRA #
STEP 5
High dose
ICS-LABA
Refer for
phenotypic
assessment
± add-on
therapy,
e.g.tiotropium,
anti-IgE,
anti-IL5/5R,
anti-IL4R
Add low dose
OCS, but
consider
side-effects
As-needed low dose ICS-formoterol * As-needed low dose ICS-formoterol ‡
As-needed short-acting β2 -agonist (SABA)
* Off-label; data only with budesonide-formoterol (bud-form)
† Off-label; separate or combination ICS and SABA inhalers
‡ Low-dose ICS-form is the reliever for patients prescribed bud-
form or BDP-form maintenance and reliever therapy
# Consider adding HDM SLIT for sensitized patients with allergic
rhinitis and FEV >70%predicted
Asthma medication options:
Adjust treatment up and down for
individual patient needs
Other
Controller option
There is no theophylline
69. GINA 2019 - Step 4 changes
PREFERRED
CONTROLLER
to prevent exacerbations
and control symptoms
PREFERRED
RELIEVER
Other
reliever option
STEP 1
As-needed
low dose
ICS-formoterol *
Low dose ICS
taken whenever
SABA is taken†
STEP 2
Daily low dose inhaled corticosteroid (ICS), or as-
needed low dose ICS-formoterol *
Leukotriene receptor antagonist (LTRA), or
low dose ICS taken whenever SABA taken †
STEP 3
Low dose
ICS-LABA
Medium dose
ICS, or
low dose
ICS+LTRA #
STEP 4
Medium dose
ICS-LABA
High dose
ICS, add-on
tiotropium,
or add-on
LTRA #
STEP 5
High dose
ICS-LABA
Refer for
phenotypic
assessment
± add-on
therapy,
e.g.tiotropium,
anti-IgE,
anti-IL5/5R,
anti-IL4R
Add low dose
OCS, but
consider
side-effects
As-needed low dose ICS-formoterol * As-needed low dose ICS-formoterol ‡
As-needed short-acting β2 -agonist (SABA)
* Off-label; data only with budesonide-formoterol (bud-form)
† Off-label; separate or combination ICS and SABA inhalers
‡ Low-dose ICS-form is the reliever for patients prescribed bud-
form or BDP-form maintenance and reliever therapy
# Consider adding HDM SLIT for sensitized patients with allergic
rhinitis and FEV >70%predicted
Asthma medication options:
Adjust treatment up and down for
individual patient needs
Other
Controller option
Step 4 treatment is
medium dose ICS-LABA;
high dose now in Step 5
70. GINA 2019 - Step 5 changes
PREFERRED
CONTROLLER
to prevent exacerbations
and control symptoms
PREFERRED
RELIEVER
Other
reliever option
STEP 1
As-needed
low dose
ICS-formoterol *
Low dose ICS
taken whenever
SABA is taken†
STEP 2
Daily low dose inhaled corticosteroid (ICS), or as-
needed low dose ICS-formoterol *
Leukotriene receptor antagonist (LTRA), or
low dose ICS taken whenever SABA taken †
STEP 3
Low dose
ICS-LABA
Medium dose
ICS, or
low dose
ICS+LTRA #
STEP 4
Medium dose
ICS-LABA
High dose
ICS, add-on
tiotropium,
or add-on
LTRA #
STEP 5
High dose
ICS-LABA
Refer for
phenotypic
assessment
± add-on
therapy,
e.g.tiotropium,
anti-IgE,
anti-IL5/5R,
anti-IL4R
Add low dose
OCS, but
consider
side-effects
As-needed low dose ICS-formoterol * As-needed low dose ICS-formoterol ‡
As-needed short-acting β2 -agonist (SABA)
* Off-label; data only with budesonide-formoterol (bud-form)
† Off-label; separate or combination ICS and SABA inhalers
‡ Low-dose ICS-form is the reliever for patients prescribed bud-
form or BDP-form maintenance and reliever therapy
# Consider adding HDM SLIT for sensitized patients with allergic
rhinitis and FEV >70%predicted
Asthma medication options:
Adjust treatment up and down for
individual patient needs
Other
Controller option
High dose ICS-LABA
Anti-IL 5R
Anti-IL 4R
76. Uncontrolled Asthma
• Poor symptoms control (frequent symptoms or
reliever use, activity limited by asthma, night
waking due to asthma)
And / Or
• Frequent exacerbation ( >2 per year) requiring
oral corticosteroids or serious exacerbation ( >1
per year ) requiring hospitalization.
77. Difficult-to-treat asthma
Asthma that is uncontrolled despite GINA Step
4 or 5 treatment or that requires such
treatment to maintain good symptom control
and reduce the risk of exacerbations.
Contributory factors may include incorrect
diagnosis, incorrect inhaler technique, poor
adherence, comorbidities.
78. Severe asthma
Severe asthma is a subset of difficult-to-treat
asthma.
It means asthma that is uncontrolled despite
adherence with maximal optimized therapy and
treatment of contributory factors, or that worsens
when high dose treatment is decreased.
It is sometimes called ‘severe refractory asthma’
since it is relatively refractory to high dose inhaled
therapy.
However, with the advent of biologic therapies,
the word ‘refractory’ is no longer appropriate.
85. Asthma with Pregnancy
Asthma control often changes during pregnancy.
For baby and mother, the advantages of actively
treating asthma markedly outweigh any potential
risks of usual controller and reliever medications.
Down-titration has a low priority in pregnancy.
Exacerbations should be treated aggressively.
86. Surgical Procedure in Asthma patient
Whenever possible, good asthma control should be
achieved preoperatively.
Ensure that controller therapy is maintained
throughout the perioperative period.
Patients on long-term high dose ICS, or having more
than 2 weeks’ OCS in the past 6 months, should
receive intra-operative hydrocortisone to reduce the
risk of adrenal crisis.
87. Take home message
No longer recommends starting with SABA
only treatment.
All adults and adolescents with asthma
should receive ICS-containing controller
treatment, to reduce their risk of serious
exacerbations and to control symptoms.